Product Description
Amitriptyline is used to treat symptoms of depression. Amitriptyline is in a class of medications called tricyclic antidepressants. It works by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance.
Mechanisms of Action: NRI Inhibitor, SRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: HolsboerMaschmeyer NeuroChemie
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Germany, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dyspareunia
Phase 2: Chronic Pain|Epileptic Encephalopathy|Erythromelalgia|Pelvic Pain|Prostatitis
Phase 1: Pudendal Neuralgia|Vulvodynia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12625000315415 |
ACTRN12625000315415 | P1 |
Completed |
Dyspareunia|Vulvodynia|Pudendal Neuralgia |
2025-05-05 |
2025-09-16 |
Treatments |
|
2020-005908-18 |
PeteGeeK | P2 |
Completed |
Epileptic Encephalopathy |
2024-12-05 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05917912 |
EASE | P2 |
Completed |
Erythromelalgia |
2024-02-29 |
50% |
2024-04-19 |
Primary Endpoints |
CTR20200406 |
CTR20200406 | P2 |
Completed |
Chronic Pain|Pelvic Pain|Prostatitis |
2023-01-05 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12624001210561 |
ACTRN12624001210561 | P3 |
Recruiting |
Dyspareunia |
2025-12-24 |
2025-12-11 |
Patient Enrollment|Primary Completion Date|Start Date|Treatments|Trial Status |
|
ACTRN12625000939493 |
ACTRN12625000939493 | P1 |
Not yet recruiting |
Pudendal Neuralgia|Dyspareunia|Vulvodynia |
None |
2025-09-29 |
Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/28/2025 |
News Article |
Wisp Launches Comprehensive Migraine Care Vertical, Innovating Category with First-Ever, Asynchronous Care |
|
06/19/2025 |
News Article |
Lundbeck Advances Leadership in Migraine With New Data at the American Headache Society 67th Annual Scientific Meeting |
|
04/22/2025 |
News Article |
Nerve Freedom Reviews [Investigated Complaints] Nerve Alive Best Neuropathy Supplement for Nerve Pain Relief Naturally |
|
04/11/2025 |
News Article |
Arialief Ingredients Under Review - What the Science Says About Customer Benefits |